骨靶向治疗（BTT）包括左旋氨磷酸（ZA）和登奥苏单抗（Denosumab）可降低乳腺癌转移性骨转移患者骨相关事件（SREs）的风险。对于长期进行BTT对SREs和BTT相关危害的影响尚不清楚，但随着这些患者的生存期延长，这一问题变得越来越重要。我们进行了一项回顾性研究，共有224名乳腺癌转移性骨转移患者在诊断后存活超过2年，并在2016年至2021年期间在我们的医院接受治疗。我们定义了3种BTT模式：（1）仅使用ZA，（2）仅使用Denosumab，（3）ZA和Denosumab联合使用。使用Fisher精确检验和Logistic回归分析评估了这些BTT模式与SREs和危害之间的关联。整体SREs的发生率为ZA组21.2%，Denosumab组8.8%，同时使用ZA和Denosumab组20%，差异无统计学意义（p = .32）。然而，仅使用Denosumab治疗的患者压缩性骨折发生率明显较低（0.7%）（p = .02）。在仅使用ZA组中观察到BTT相关危害的发生率为5.8%，在仅使用Denosumab组中为11.7%，同时使用ZA和Denosumab组为14.3%，差异无统计学意义（p = .37）。肿瘤科医生在选择药物时可能会有更大的灵活性，包括BTT的给药频率。我们的研究结果显示，在评估的BTT方案中，对于整体SRE的预防和BTT相关危害的发展之间并没有显著差异。版权所有 © 2023 Elsevier Inc.。保留所有权利。

Bone-targeted therapy (BTT) including zoledronic acid (ZA) and denosumab decreases the risk of skeletal-related events (SREs) in patients with metastatic breast cancer (MBC) and bone metastasis. The impacts from prolonged BTT on SREs and BTT-associated harms are unknown and are becoming important to understand as these patients survive for longer periods.We conducted a retrospective study of 224 patients with MBC and bone metastasis who survived for more than 2 years after diagnosis and received treatment at our institution between 2016 and 2021. We defined 3 BTT patterns: (1) ZA only, (2) denosumab only, (3) both ZA and denosumab. The association between these BTT patterns and SREs and harms was assessed using Fisher exact test and logistic regression.Rates of SREs overall were 21.2% of patients given ZA only, 8.8% of those given denosumab only, and 20% of those given both, without statistically significant differences (p = .32). However, those treated with denosumab only had significantly fewer compression fractures (0.7%) (p = .02). BTT-associated harm was observed in 5.8% of the ZA-only group, 11.7% of the denosumab-only group, and 14.3% of the group given both, without statistically significant differences (p = .37).Oncologists may have increased flexibility regarding the frequency of administration of BTT along with their choice of agent. Our study showed no significant difference in the prevention of overall SRE or development of BTT-associated harms between the BTT regimens evaluated.Copyright © 2023 Elsevier Inc. All rights reserved.